Mizolastine


Concise Prescribing Info
Indications/Uses
Allergic conditions.
Dosage/Direction for Use
Adult : PO 10 mg/day.
Dosage Details
Oral
Allergic conditions
Adult: 10 mg daily.
Child: ≥12 yr: 10 mg daily.
Elderly: 10 mg daily.
Contraindications
Significant cardiac or hepatic disease; electrolyte imbalance, particularly hypokalaemia; known or suspected QT prolongation. Clinically significant bradycardia.
Special Precautions
May impair ability to drive or operate machinery. Elderly. Pregnancy (avoid in 1st trimester) and lactation.
Adverse Reactions
Dry mouth, diarrhoea, abdominal pain, nausea; transient drowsiness, headache, dizziness; anxiety and depression; raised liver enzymes: low neutrophil count; transient asthenia, increased appetite associated with wt gain; allergic reactions e.g. angioedema, generalised rash/urticaria, pruritus and hypotension; tachycardia, palpitations; vasovagal attack; arthralgia and myalgia.
Potentially Fatal: Anaphylaxis.
Overdosage
General symptomatic treatment with cardiac monitoring including QT interval and cardiac rhythm for at least 24 hr is recommended. Haemodialysis may not be helpful.
Drug Interactions
Antidepressants and anxiolytics may enhance sedative effect. Potent inhibitors of or substrates for the hepatic metabolism of mizolastine (e.g. cimetidine, ciclosporin, nifedipine) may alter its metabolism.
Potentially Fatal: Increased risk of cardiac arrhythmias with drugs known to prolong the QT interval e.g. class I and III antiarryhthmics. Increased plasma concentrations with macrolide antibiotics and imidazole antifungals.
Action
Description: Mizolastine, a non-sedating antihistamine, blocks histamine H1-receptors on effector cells of the GI tract, blood vessels and respiratory tract. It also has mast-cell stabilising properties.
Pharmacokinetics:
Absorption: Absorbed rapidly from the GI tract (oral); peak plasma concentrations after 1.5 hr.
Distribution: Protein-binding: 98%.
Metabolism: By glucuronidation (main pathway) or by cytochrome P450 isoenzyme CYP3A4 forming inactive hydroxylated metabolites.
Excretion: 13 hr (elimination half-life).
Storage
Do not store above 25°C.
Disclaimer: This information is independently developed by MIMS based on Mizolastine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in